Interim Report May 7th
Some sales are already happening in Sweden. Marketing authorizations have now been received in all 13 EU countries that participated in the licensing process, and Terclara is coming to market over-the-counter (OTC) in countries like Italy and the Netherlands, though it requires a prescription in Finland, for example. This comment from the CEO seems quite positive: “A majority of ~1,400 Swedish pharmacies now have MOB-015 available on the shelf under the brand name Terclara® and interest is exceeding the chains’ forecasts. The pharmacy chains are increasing their orders after consumer marketing began around the end of March due to the fact that the product occasionally has sold out at several of the pharmacy chains”
Sales in other European countries are starting off sluggishly. Based on previous comments, I thought sales would have started faster at least in the other Nordic countries, but it seems we might have to wait for a new terbinafine supplier before sales can expand. An application for a new terbinafine supplier was submitted in April, and according to the press release, the authorization should be obtained before the end of the year.
The cash position looks poor at a quick glance, but hopefully, the exercise of warrants will fix the situation. The stock has been on a strong upward trend lately, and at these prices, the warrants expiring in June are set to bring a lot of money into the coffers. This is, of course, entirely dependent on the stock price and how many warrants are ultimately exercised. Does anyone here have any insight or previous experience regarding what is likely to happen with the warrants? Will the stock price drop closer to the subscription price, and are the warrants a risky investment in that sense?